Evidence map›Paper›PMID 39535582›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Dimdazenil for the treatment of insomnia: a systematic review and narrative synthesis.

Shan Ran, Shouhuan Liu, Kewen Yan, Xueyi Li, Min Wu, Hanrui Peng, Tieqiao Liu, Zejun Li

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shan RanPsychiatric Hospital of Ziyang, Ziyang, 641300, Sichuan, China.
Shouhuan LiuDepartment of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China.
Kewen YanDepartment of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China.
Xueyi LiThe Third People's Hospital of Qujing, Qujing, 655000, Yunnan, China.
Min WuDepartment of Psychiatry, National Center for Mental Disorders, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, China.
Hanrui PengDepartment of Psychiatry, National Center for Mental Disorders, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, China.
Tieqiao LiuDepartment of Psychiatry, National Center for Mental Disorders, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, China. liutieqiao123@csu.edu.cn.
Zejun LiDepartment of Psychiatry, National Center for Mental Disorders, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, China. 228212219@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInsomnia is a common sleep disorder affecting approximately 10-20% of adults worldwide. Despite various available treatment modalities, significant gaps remain in improving sleep maintenance and reducing functional impairments.

objectiveTo systematically review and synthesize studies on the efficacy and safety of Dimdazenil for the treatment of insomnia.

methodsA comprehensive search of multiple databases and websites was conducted to identify published and unpublished trials from inception to July 19, 2024. Due to the limited number of studies available, quantitative data were synthesized narratively.

resultsThis synthesis included four randomized controlled trials. The primary efficacy endpoints of these studies met the predetermined criteria for superiority. Dimdazenil significantly improved certain objective and subjective sleep measures in patients with insomnia, including reduced sleep latency and longer total sleep duration. Importantly, these outcomes were achieved without causing significant excessive daytime drowsiness or impairing daytime functionality. Furthermore, Dimdazenil demonstrated a generally acceptable safety profile and was well tolerated. Most evaluation indicators related to withdrawal symptoms, drug residues, and rebound effects did not show significant statistical differences. LIMITATIONS: The number of included studies and sample sizes were small, and there is a lack of data on the long-term efficacy and safety of Dimdazenil.

conclusionsDimdazenil offers significant benefits in improving sleep onset and maintenance in patients with insomnia. It presents a favorable safety and tolerability profile while preserving daytime functioning. Future studies should extend the duration and scale to assess the long-term efficacy and safety of Dimdazenil across diverse populations.

Indexed as

GABA ModulatorsSleep Initiation and Maintenance DisordersHumansRandomized Controlled Trials as TopicGABA ModulatorsDimdazenilEfficacyInsomniaRandomized controlled trialsSafety

Identifiers

PMID39535582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.